Abstract
| Lingua originale | English |
|---|---|
| pagine (da-a) | - |
| Numero di pagine | 5 |
| Rivista | Haematologica |
| Volume | 97 |
| Stato di pubblicazione | Published - 2012 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
Cita questo
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency. / Napolitano, Mariasanta; Canella, Alessandro; Giansily-Blaizot, Muriel; Pinotti, Mirko; Mariani, Guglielmo; Rizzotto, Lara; Mari, Rosella; Lapecorella, Mario; Branchini, Alessio; Bernardi, Francesco; Napolitano, Mariasanta.
In: Haematologica, Vol. 97, 2012, pag. -.Risultato della ricerca: Article
}
TY - JOUR
T1 - Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency.
AU - Napolitano, Mariasanta
AU - Canella, Alessandro
AU - Giansily-Blaizot, Muriel
AU - Pinotti, Mirko
AU - Mariani, Guglielmo
AU - Rizzotto, Lara
AU - Mari, Rosella
AU - Lapecorella, Mario
AU - Branchini, Alessio
AU - Bernardi, Francesco
AU - Napolitano, Mariasanta
PY - 2012
Y1 - 2012
N2 - We report 2 asymptomatic homozygotes for the nonsense p.R462X mutation affecting the carboxy-terminus of coagulation factor VII (FVII, 466 aminoacids). FVII levels of 3-5% and 2.7 ± 0.4% were found in prothrombin time-based and activated factor X (FXa) generation assays with human thromboplastins. Noticeably, FVII antigen levels were barely detectable (0.7 ± 0.2%) which suggested a gain-of-function effect. This effect was more pronounced with bovine thromboplastin (4.8 ± 0.9%) and disappeared with rabbit thromboplastin (0.7 ± 0.2%). This suggests that the mutation influences tissue factor/FVII interactions. Whereas the recombinant rFVII-462X variant confirmed an increase in specific activity (~400%), a panel of nonsense (p.P466X, p.F465X, p.P464X, p.A463X) and missense (p.R462A, p.R462Q, p.R462W) mutations of the FVII carboxy-terminus resulted in reduced secretion but normal specific activity. These data provide evidence for counteracting pleiotropic effects of the p.R462X mutation, which explains the asymptomatic FVII deficiency, and contributes to our understanding of the role of the highly variable carboxy-terminus of coagulation serine proteases.
AB - We report 2 asymptomatic homozygotes for the nonsense p.R462X mutation affecting the carboxy-terminus of coagulation factor VII (FVII, 466 aminoacids). FVII levels of 3-5% and 2.7 ± 0.4% were found in prothrombin time-based and activated factor X (FXa) generation assays with human thromboplastins. Noticeably, FVII antigen levels were barely detectable (0.7 ± 0.2%) which suggested a gain-of-function effect. This effect was more pronounced with bovine thromboplastin (4.8 ± 0.9%) and disappeared with rabbit thromboplastin (0.7 ± 0.2%). This suggests that the mutation influences tissue factor/FVII interactions. Whereas the recombinant rFVII-462X variant confirmed an increase in specific activity (~400%), a panel of nonsense (p.P466X, p.F465X, p.P464X, p.A463X) and missense (p.R462A, p.R462Q, p.R462W) mutations of the FVII carboxy-terminus resulted in reduced secretion but normal specific activity. These data provide evidence for counteracting pleiotropic effects of the p.R462X mutation, which explains the asymptomatic FVII deficiency, and contributes to our understanding of the role of the highly variable carboxy-terminus of coagulation serine proteases.
KW - FACTOR VII DEFICIENCY, MOLECULAR VARIANTS
UR - http://hdl.handle.net/10447/71163
M3 - Article
VL - 97
SP - -
JO - Haematologica
JF - Haematologica
SN - 0390-6078
ER -